Trend in the prevalence of metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN (Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease) studies

Sadegh Mazaheri-Tehrani; Motahar Heidari-Beni; Mostafa Qorbani; Maryam Yazdi; Roya Kelishadi

doi:10.6065/apem.2550042.021

Ann Pediatr Endocrinol Metab > Volume 30(6); 2025 > Article

Mazaheri-Tehrani, Heidari-Beni, Qorbani, Yazdi, and Kelishadi: Trend in the prevalence of metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN (Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease) studies

Original Article

Annals of Pediatric Endocrinology & Metabolism 2025;30(6): 296-304.

Published online: December 31, 2025

DOI: https://doi.org/10.6065/apem.2550042.021

Trend in the prevalence of metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN (Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease) studies

Sadegh Mazaheri-Tehrani^1,²

, Motahar Heidari-Beni¹

, Mostafa Qorbani³

, Maryam Yazdi¹

, Roya Kelishadi¹

¹Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

²Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

³Non-Communicable Diseases Research Diseases, Alborz University of Medical Sciences, Karaj, Iran

Address for correspondence: Motahar Heidari-Beni Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Hezarjerib St, Isfahan University of Medical Sciences, Isfahan, Iran Email: heidari.motahar@gmail.com

Address for co-correspondence to: Maryam Yazdi Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Hezarjerib St, Isfahan University of Medical Sciences, Isfahan, Iran Email: myazdi86@gmail.com

Received January 21, 2025 Revised March 14, 2025 Accepted May 8, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Cardiometabolic risk factors can originate in childhood, especially in overweight individuals. In this study, we aimed to determine the trends in the prevalence of metabolic phenotypes among Iranian children and adolescents.

Methods

We determined the trends of the data from 3 nationwide school-based studies in Iran from 2003 to 2016 (the CASPIAN [Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease] studies). A total of 8,711 individuals (49.6% boys) aged 10–18 years were studied. Obesity and normal weight were considered as an age- and sex-specific body mass index > 95th percentile and between the 5th to 85th percentile, respectively. Metabolic syndrome (MetS) was defined according to the modified Adult Treatment Panel III criteria for children and adolescents. Children were categorized into 4 groups: metabolically healthy obesity (MHO), metabolically unhealthy obesity (MUO), metabolically healthy normal weight, and metabolically unhealthy normal weight (MUNW).

Results

Over 13 years, the prevalence of obesity increased significantly from 9.8% to 11.6% (p<0.001), whereas that of MetS did not change significantly (from 5.35% in 2003–2004 to 7.76% in 2009–2010 and 4.45% in 2015-2016, p=0.83). The prevalence of MHO increased significantly from 7.1% in 2004 to 9.6% in 2016 (p=0.005). However, the change in prevalence was not significant for MUO and MUNW.

Conclusions

From 2003 to 2016, the prevalence of MetS and metabolic phenotypes except MHO did not change significantly among Iranian children. The marginal increase in MHO prevalence should be considered, as shifts from this phenotype to unhealthy phenotypes may influence the risk of developing noncommunicable diseases in adulthood.

Keywords: Pediatric obesity, Metabolic syndrome, Metabolically benign obesity, Iran

Highlights

· Data from repeated nationwide, school-based surveys conducted in Iran between 2003 and 2016 were used to assess trends in metabolic phenotypes among children and adolescents.

· Childhood obesity increased significantly over time, while the prevalence of metabolic syndrome remained stable.

· Metabolically healthy obesity showed a modest but significant increase, underscoring the importance of early cardiometabolic prevention, as this phenotype may progress to metabolically unhealthy states.

Introduction

In recent decades, the prevalence of weight disorders has increased among children and adolescents [1]. According to the World Health Organization (WHO), in 2022, more than 390 million children aged 5–19 years were overweight or obese [2]. According to a metaanalysis from 2001 to 2021, the prevalence of obesity among more than 2.5 million Iranian children was 11.4 % [3]. Another meta-analysis demonstrated that the prevalence of overweight and obesity among Iranian children up to 2022 was 12.4 % and 10.3 %, respectively [4]. There are associations between childhood obesity and cardiovascular diseases (CVDs) in adulthood. Obese children and adolescents are approximately 5 times more likely to remain obese in adulthood compared to their non-obese counterparts [5,6].

Despite the risk of various metabolic disorders among overweight and obese children, some of them are metabolically healthy. In this regard, the term "metabolically healthy obesity" (MHO) has been utilized in several investigations [7-9]. According to this concept, using anthropometrics and metabolic syndrome (MetS) parameters, individuals are categorized into 4 groups of MHO, metabolically unhealthy obese (MUO), metabolically healthy normal weight (MHNW), and metabolically unhealthy normal weight (MUNW) [8]. Compared to the MHNW, MHO cases are at higher risk of converting to MUO and developing noncommunicable diseases (NCDs). Thus, preventive interventions should be focused on MHO subjects [10]. Various studies have shown that the increased risk of NCDs in individuals with MUO compared to MHO was due to distribution and function of adipose tissue [11,12]. Individuals with MUO have lower subcutaneous fat, higher visceral fat, and greater fat accumulation in hepatic and muscular tissues compared to the MHO cases. These factors contribute to insulin resistance in MUO individuals [13].

Studies have assessed the prevalence of metabolic phenotypes among children and adolescents in different regions and reported various findings [14-16]. This might be due to differences in criteria for defining metabolic phenotypes, the age range of the participants, and genetic differences. However, there are limited studies regarding the trends in the prevalence of metabolic phenotypes. A multisection cross-sectional survey of South Korean youths demonstrated that the prevalence of MHO did not change significantly between 2011 and 2019. However, the prevalence of overweight and obesity increased significantly during this period [17]. On the other hand, a serial investigation among US adolescents showed a significant increase in MHO prevalence [18].

Investigation of the trends of metabolic phenotypes among children and adolescents in a community reflects the impact of health interventions over time and shows a path for further preventive interventions. In addition, implementing appropriate preventive measures during childhood could diminish the burden of NCDs in adulthood. However, no longitudinal or repeated surveys have investigated the changes in metabolic phenotypes in Iranian children and adolescents. In the present study, we examined the trends of prevalence of metabolic phenotypes of obesity in Iranian children and adolescents over a span of 13 years.

Materials and methods

1. Study design and patients

This study was performed using data obtained from the "Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease (CASPIAN) studies" of Iranian children and adolescents. These multisection cross-sectional investigations were conducted in 30 provinces of Iran and assessed the possible risk factors for NCDs. Data of Iranian children and adolescents were gathered through CASPIAN I (2003– 2004), CASPIAN-III (2009–2010), and CASPIAN V (2015– 2016). Detailed information on the survey design and methods of each survey has been published previously [19-21]. The protocol of the current study was approved by the ethical committee of Isfahan University of Medical Sciences (IR.MUI.MED.REC.1402.162).

The data were collected via interviews; questionnaires completed by children and their parents; and measurement of biochemical parameters in blood samples, anthropometric features, and blood pressure (BP). CASPIAN-I was performed from 2003 to 2004 in 23 provinces of Iran. The sample size was 21,111 children and adolescents aged 6–18 years. Anthropometrics and BP were evaluated in all participants, and biochemical parameters were measured in 4811 participants [19]. CASPIAN-III was conducted between 2009–2010 in 27 provinces of Iran. The total sample size was 5,528 students aged 10–18 years [20]. CASPIAN-V was performed in 2015–2016 among 14,400 students aged 7–18 years. Blood samples and biochemical items were collected from 4,200 participants [21]. The flowchart of participant inclusion is shown in Fig. 1. After explaining the aim and objectives of the investigation, written and verbal consent was obtained from both participants and their parents.

2. Physical measurements

A team of qualified healthcare providers conducted the physical examination following established protocols and utilizing calibrated instruments. Weight was recorded in light clothing to the nearest 0.1 kg using a SECA digital weighing scale (SECA, Germany). Height was measured without shoes to the nearest 0.1 cm while the participants stood with their shoulders in a natural position [22]. Body mass index (BMI) was determined by dividing weight in kilograms by the square of height in meters. The WHO growth charts were used to classify BMI [23]. Waist circumference (WC) was assessed with a nonelastic tape measure, positioned at a point equidistant from the lower edge of the rib cage and the iliac crest, after a normal expiration and was recorded to the nearest 0.1 cm. BP was assessed on the right arm with the participant in a seated position utilizing a mercury sphygmomanometer equipped with a suitable cuff size. Measurements were performed twice at 5-minute intervals. Both systolic and diastolic BPs were documented, and the average value was calculated [24].

3. Laboratory data

Following a 12-hour overnight fasting period, a 6-mL venous blood sample was obtained from eligible participants. All collection tubes underwent centrifugation at 2,500–3,000 g for 10 minutes. Immediately postcentrifugation, serum samples were divided into 200-μL aliquots and preserved at -70°C. Utilizing a cold chain protocol, all samples were transported to the Isfahan Mahdieh Laboratory. Fasting blood sugar (FBS), triglyceride (TG), total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol (HDL-C) levels were determined enzymatically using a Hitachi auto-analyzer (Tokyo, Japan).

4. Definitions

All participants regardless of CASPIAN phase were categorized into 4 groups based on obese or normal weight and metabolically healthy or unhealthy. According to the WHO growth curve, general obesity is defined as a BMI higher than the 95th age- and sex-specific percentile. Normal weight is a BMI between the 5th to 85th percentiles for age and sex [23]. MetS was defined according to the modified Adult Treatment Panel III criteria for children and adolescents [25]. FBS greater than 110 mg/dL, fasting serum TG higher than 110 mg/dL, serum HDL-C less than 40 mg/dL, hypertension (systolic or diastolic BP higher than 90th age-, sex-, and height-specific percentile) [26], and abdominal obesity (WC greater than the 90th age- and sex-specific percentile) are considered as the parameters of MetS. If a person had 3 of the 5 parameters, the participant was categorized as metabolically unhealthy. According to these criteria, participants were categorized into 4 groups of MHO, MUO, MHNW, and MUNW.

5. Statistical analysis

Analyses were based on complete case data. Descriptive statistics were reported for each CASPIAN phase. Categorical variables were expressed as frequencies and percentages. Comparisons across the 3 survey time points (CASPIAN-I: 2003–2004, CASPIAN-III: 2009–2010, CASPIAN-V: 2015–2016) were performed to identify trends in prevalence over time. To test for significant changes in prevalence, we used the Cochran-Armitage trend test for binary variables and Kendall's tau-c test for ordinal data. Chi-square tests were used where appropriate to assess differences in proportions between subgroups, such as sex. All trend analyses were stratified to explore sex-specific patterns, and results were presented separately for boys and girls. A 2-sided P-value <0.05 was considered statistically significant. No adjustments were performed for multiple comparisons due to the descriptive and exploratory nature of the study. Potential confounding factors were considered in interpretation but were not adjusted through multivariable modeling, given the focus on unadjusted trends over time in repeated cross-sectional surveys. All analyses were conducted using Stata 17.0 (StataCorp LLC, TX).

Results

Demographic characteristics of participants in each phase of the CASPIAN studies are presented in Table 1. Overall, 48% of participants in CASPIAN-V, 50.2% in CASPIAN-III, and 46.5% in CASPIAN-I were female. Table 1 and Fig. 2 also show the prevalence of MetS and its components among participants in each survey. The prevalence of MetS increased from 5.35% in CASPIAN-I to 7.76% in CASPIAN-III and then decreased to 4.45% in CASPIAN-V. According to Kendall’s tau-c test, the change was not significant (P=0.830). Regarding MetS components, the data show a significant increase in abdominal obesity over the timeline (8.32% to 14.11%, P<0.001), while the prevalence of hypertriglyceridemia (28.89% to 21.77%, P<0.001) and low HDL-C (41.67% to 30.95%, P<0.001) decreased significantly. The prevalence of high BP from 2002 to 2015 fluctuated, while the prevalence of high FBS significantly increased (0.91% to 4.46%, P<0.001). The prevalence of general obesity decreased from 9.8% in CASPIAN-I to 8.9% in CASPIANIII and then increased to 11.6% in CASPIAN-V. Overall, its prevalence significantly increased (P<0.001).

We also reported the prevalence of MetS and its components, as well as general obesity in each gender (Table 1). Among boys, the prevalence of general obesity increased from 9.6% (CASPIAN-I) to 10.1% (CASPIAN-III) and 12.6% (CASPIAN-V). However, its trend was not statistically significant (P=0.139). The prevalence of MetS significantly decreased among boys from 6.62% (CASPIAN-I) to 4.61% (CASPIAN-V) (P=0.022). As in the general population, the prevalence of hypertriglyceridemia and low HDL-C significantly decreased during the studied time period in both sexes (P=0.003 and P<0.001, respectively). Additionally, the prevalence of high FBS significantly increased in both girls and boys, the prevalence of high BP significantly decreased among boys (P=0.008), and the prevalence of abdominal obesity significantly increased among girls (P<0.001).

Table 2 shows the prevalence of the metabolic phenotypes over 13 years in both the general population and by sex. The prevalence of MUO and MUNW phenotypes increased from CASPIAN-I to CASPIAN-III, but a decrease occurred from CASPIAN-III to CASPIAN-V. The prevalence of MHO significantly increased from CASPIAN-I to CASPIAN-V (P=0.005), while the prevalence of MHNW significantly decreased (P=0.044) (Fig. 3).

Discussion

According to nationwide studies in Iran, we observed a stationary trend in the prevalence of MetS, MUO, and MUNW phenotypes from 2003 to 2016. However, the prevalence of MHO indicated a marginal increase, and that of MHNW showed a marginal decrease during this time period. These results are similar to those of an investigation in Korea from 2011 to 2019 [17]. However, that study reported a not significant change in the prevalence of MHO (from 34.8% to 35.7%), with a considerably higher rate than that in our population. Another research among US adolescents aged 12–19 years indicated a significant increase in the prevalence of MHO from 13.2% to 16.4% during 1999–2018. As in our findings, the prevalence of MHNW showed a significant decrease from 68.1% to 61.7% among their population [18].

Additionally, a significant increase in the prevalence of abdominal obesity and high FBS and a significant decrease in those of hypertriglyceridemia and low HDL-C levels were observed in our population during this period. The prevalence of obesity increased in our study, which is consistent with the global increasing trend of obesity in youths [2,27]. This increase in the prevalence of obesity among Iranian children and adolescents might be attributed to shifts in lifestyle, which have led to greater accessibility to food and fastfood options, along with increased exposure to mass media and computer games among young people [3]. The WHO recommends that children and adolescents aged 5–17 years engage in a minimum of 60 minutes of moderate to vigorous physical exercise daily [28]. According to this criterion, 29.5% of Iranian girls and 20.5% of boys are considered physically active, highlighting that a large number of Iranian youths do not perform optimal levels of physical activity [29]. This sedentary behavior has resulted in various health complications that can persist into adulthood [30].

MHO refers to individuals with obesity without cardiometabolic disorders. The prevalence of MHO varies between regions, ranging from 7% to 87% [9,31,32]. This variation might be due to different definitions of MetS, genetic variations, and environmental factors. Individuals with MHO are at higher risk of transitioning to an unhealthy metabolic state [33] and have a higher risk of CVDs [34]. Therefore, recognizing MHO individuals, especially in early life, would help healthcare providers prevent progression of NCDs during adulthood. The MHO prevalence among Iranian youth was approximately 7.5% in 2003–2016, which is lower than in other investigations among Korean adolescents (39% in 2011–2019) [17], European youths (41.1% in 2014–2019) [32], United States adolescents (15.4% in 1999–2018) [18], and Canadian children (25% in 2010) [35]. Differences in lifestyle and environmental factors in addition to genetic predispositions can contribute to this variation [36]. However, differences in cutoff points used for MetS definitions and the year of investigation might affect the results, as temporal changes in environmental exposures, lifestyle patterns, and measurement tools can influence the observed prevalence. This increase in MHO should be addressed by the healthcare system, and measures should be taken to prevent unhealthy metabolic status.

The term MUNW or metabolically obese normal weight was first introduced by Ruderman et al. [37] in 1981 and refers to normal-weight individuals with metabolic abnormality. The presence of this phenotype among youths increases the risk of NCDs [38]. In all CASPIAN investigations, the prevalence of MUNW in adolescents was higher than that of MUO individuals. Therefore, even children with normal weight could be at risk for metabolic abnormalities, and repeated measurements of MetS components are pivotal [38].

This study provides the temporal trend of obesity of Iranian children and adolescents up to 2015 and also the changes in metabolic profile. To the best of our knowledge, this is the first investigation in Iran and the third across the world to determine the temporal trends of metabolic phenotypes of obesity among children and adolescents. In addition, the sample size of our study was much larger than in previous studies among Korean [17] and United States [18] youths. However, there are some limitations that should be considered. First is the decrease in activity required during the coronavirus disease 2019 pandemic [28]. Second, due to the multi– cross-sectional manner of this survey, we were unable to assess causal relations. Third, insufficient data on pubertal stage prevented us from distinguishing between prepubertal and pubertal participants. Future studies should aim to include detailed pubertal assessments to better understand how developmental stage influences the outcomes under investigation. Updated investigations are needed to clarify the changes in metabolic phenotypes over time. Further longitudinal studies would better clarify the transition rate between phenotypes.

In conclusion, according to multi–cross-sectional investigations among Iranian children and adolescents from 2003 to 2016, the prevalence of MetS and metabolic phenotypes other than MHO indicated a stationary trend. However, significant increase in abdominal obesity and high FBS and significant decrease in hypertriglyceridemia and low HDL-C levels were observed over the 13 studied years. Preventive interventions targeting children with MHO might decrease the burden of NCDs during adulthood.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study was conducted as project number 3402202, supported by Isfahan University of Medical Sciences. The funds allocated for conducting this project were received by Dr. Roya Kelishadi for the implementation of the study.

Data availability

The data that support the findings of this study can be provided by the corresponding author upon reasonable request.

Acknowledgments

This project was conducted using the data of 3 national school-based surveillance programs. The authors are thankful for the large team working on these national projects and for all the participants who cooperated with this study.

Author contribution

Conceptualization: SMT, MHB, MQ, MY, RK; Data curation: MY, RK; Funding acquisition: RK; Methodology: SMT, MHB, MQ, MY, RK; Project administration: MY, RK; Writing - original draft: SMT, MHB, MQ, MY; Writing - review & editing: SMT, MHB, MQ, MY, RK

Fig. 1.

Study flowchart of included participants. CASPIAN, Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease; BMI, body mass index; WC, waist circumference; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; FBS, fasting blood sugar; BP, blood pressure.

Fig. 2.

Prevalence of MetS and its components among participants across 3 nationwide cross-sectional studies in Iran (CASPIAN studies). CASPIAN, Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease; FBS, fasting blood sugar; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; MetS, metabolic syndrome; TG, triglycerides; WC, waist circumference.

Fig. 3.

Prevalence of metabolic phenotypes across 3 nationwide cross-sectional studies in Iran (CASPIAN studies). CASPIAN, Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease; MUO, metabolically unhealthy obese; MUNW, metabolically unhealthy normal weight; MHO, metabolically healthy obese.

Table 1.

Prevalence of general obesity and MetS and its components among participants across 3 nationwide cross-sectional studies in Iran (CASPIAN studies)

Variable	CASPIAN-I (2003–2004)		CASPIAN-III (2009–2010)		CASPIAN-V (2015–2016)		P-trend
Variable	Total No.	No. (%)	Total No.	No. (%)	Total No.	No. (%)	P-trend
Total sample
General obesity	3,550	349 (9.8)	5,615	498 (8.9)	10,500	1,221 (11.6)	<0.001^*
MetS	3,348	179 (5.35)	2,885	224 (7.76)	2,494	111 (4.45)	0.830
No. of components of Mets
0		1,085 (32.41)		938 (32.51)		984 (39.45)
1		1,431 (42.74)		1,166 (40.42)		928 (37.21)
2		653 (19.5)		557 (19.31)		471 (18.89)
3		148 (4.42)		196 (6.79)		98 (3.93)
≥4		31 (0.93)		28 (1.04)		13 (0.52)
Abdominal obesity	3,545	295 (8.32)	5,618	549 (9.77)	10,576	1,492 (14.11)	<0.001^*
Hyper TG	3,565	1,030 (28.89)	4,591	1,155 (25.16)	3,013	656 (21.77)	<0.001^*
High FBS	3,518	32 (0.91)	4,481	200 (4.46)	3,015	128 (4.25)	<0.001^*
Low HDL-C	3,561	1,484 (41.67)	3,970	1,537 (38.72)	3,015	933 (30.95)	<0.001^*
High BP	3,402	608 (17.87)	4,264	998 (23.41)	8,997	1,583 (17.59)	0.219
Boys
General obesity	1,646	158 (9.6)	2,817	284 (10.1)	5,446	687 (12.6)	0.139
MetS	1,571	104 (6.62)	1,418	93 (6.56)	1,345	62 (4.61)	0.022^*
Abdominal obesity	1,651	193 (11.69)	2,823	261 (9.25)	5,504	791 (14.37)	<0.001^*
Hyper TG	1,659	459 (27.67)	2,329	609 (26.15)	1,635	346 (21.16)	0.003^*
High FBS	1,654	21 (1.27)	2,280	81 (3.55)	1,637	73 (4.46)	<0.001
Low HDL-C	1,657	682 (41.16)	1,996	727 (36.42)	1,637	516 (31.52)	<0.001^*
High BP	1,580	346 (21.9)	2,075	412 (19.86)	4,614	784 (16.99)	0.008^*
Girls
General obesity	1,904	191 (10)	2,798	214 (7.6)	5,054	534 (10.6)	<0.001^*
MetS	1,777	75 (4.22)	1,467	131 (8.93)	1,149	49 (4.26)	0.063
Abdominal obesity	1,894	102 (5.39)	2,795	288 (10.3)	5,072	701 (13.82)	<0.001^*
Hyper TG	1,906	571 (29.96)	2,262	546 (24.14)	1,378	310 (22.5)	<0.001^*
High FBS	1,864	11 (0.59)	2,201	119 (5.41)	1,378	55 (3.99)	<0.001^*
Low HDL-C	1,904	802 (42.12)	1,974	810 (41.03)	1,378	417 (30.26)	<0.001^*
High BP	1,822	262 (14.38)	2,189	586 (26.77)	4,383	799 (18.23)	0.406

MetS, metabolic syndrome; CASPIAN, Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease; TG, triglyceride; FBS, fasting blood sugar; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure.

MetS definition based on Cook et al. [25] 2003 (National Cholesterol Education Program, Adult Treatment Panel III criteria).

^* P <0.05, statistically significant differences.

Table 2.

Prevalence of metabolic phenotypes of obesity among participants across 3 nationwide cross-sectional studies in Iran (CASPIAN studies)

Metabolic phenotypes of obesity	CASPIAN-I (2003–2004)	CASPIAN-III (2009–2010)	CASPIAN-V (2015–2016)	P-trend
Total sample	3,342	2,882	2,487
MUO	88 (2.6)	106 (3.7)	37 (1.5)	0.086
MUNW	91 (2.7)	118 (4.1)	74 (3)	0.20
MHO	236 (7.1)	181 (6.3)	238 (9.6)	0.005^*
MHNW	2,927 (87.6)	2,477 (85.9)	2,138 (86.0)	0.044^*
Male	1,566	1,416	1,340
MUO	47 (3)	51 (3.6)	25 (1.9)	0.013^*
MUNW	57 (3.6)	42 (3)	37 (2.8)	0.403
MHO	102 (6.5)	112 (7.9)	143 (10.7)	0.057
MHNW	1,360 (86.8)	1,211 (85.5)	1,135 (84.7)	0.889
Female	1,776	1,466	1,147
MUO	41 (2.3)	55 (3.8)	12 (1)	0.971
MUNW	34 (1.9)	76 (5.2)	37 (3.2)	0.011^*
MHO	134 (7.5)	69 (4.7)	95 (8.3)	0.039^*
MHNW	1,567 (87.6)	1,266 (86.4)	1,003 (87.4)	0.004^*

CASPIAN, Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease; MUO, metabolically unhealthy obesity; MUNW, metabolically unhealthy normal weight; MHO, metabolically healthy obesity; MHNW, metabolically healthy normal weight.

^* P <0.05, statistically significant differences.

References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017;390:2627-42.

2. World Health Organization. Obesity and overweight [Internet]. Geneva (Switzerland): World Health Organization; 2025 [cited 2024 Oct 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

3. Akbari H, Mohammadi M. The prevalence of obesity in iranian children: a systematic review and meta-analysis. J Pediatr Rev 2022;10:93-102.

4. Nemati SM, Mikaeili N, Hadi A. Prevalence of obesity in iranian children: a systematic review and meta-analysis. Casp J Pediatr 2022;8:748-59.

5. Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev 2016;17:95-107.

6. Sommer A, Twig G. The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: a systematic review. Curr Diab Rep 2018;18:91.

7. Vukovic R, Dos Santos TJ, Ybarra M, Atar M. Children with metabolically healthy obesity: a review. Front Endocrinol (Lausanne) 2019;10:865.

8. Damanhoury S, Newton AS, Rashid M, Hartling L, Byrne JL, Ball GD. Defining metabolically healthy obesity in children: a scoping review. Obes Rev 2018;19:1476-91.

9. Blüher M. Metabolically healthy obesity. Endocr Rev 2020;41:bnaa004.

10. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med 2013;159:758-69.

11. Zhao JY, Zhou LJ, Ma KL, Hao R, Li M. MHO or MUO? White adipose tissue remodeling. Obes Rev 2024;25:e13691.

12. An SM, Cho SH, Yoon JC. Adipose tissue and metabolic health. Diabetes Metab J 2023;47:595-611.

13. Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts 2017;10:207-15.

14. Heshmat R, Hemati Z, Payab M, Hamzeh SS, Motlagh ME, Shafiee G, et al. Prevalence of different metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN V study. J Diabetes Metab Disord 2018;17:211-21.

15. Pizano-Zárate ML, Horta-Baas G, Nuñez-Hernández JA, Montiel-Jarquín ÁJ, Tolentino-Dolores M, Hernández-Trejo M, et al. Prevalence and characteristics of the metabolically healthy obese phenotype in children and adolescents in a Mexican state. Endocrinol Diabetes Nutr (Engl Ed) 2020;67:625-35.

16. Cai S, Dang J, Zhong P, Ma N, Liu Y, Shi D, et al. Sex differences in metabolically healthy and metabolically unhealthy obesity among Chinese children and adolescents. Front Endocrinol (Lausanne) 2022;13:980332.

17. Kim HY, Kim JH. Temporal trends in the prevalence of metabolically healthy overweight and obesity in Korean youth: data from the Korea National Health and Nutrition Examination Survey 2011-2019. Ann Pediatr Endocrinol Metab 2022;27:134-41.

18. Liu J, Park YM, Ma J, Lavie CJ. Trends in metabolic phenotypes of obesity among US adolescents, NHANES 1999-2018. Mayo Clin Proc 2023;98:633-6.

19. Motlagh ME, Kelishadi R, Ardalan G, Gheiratmand R, Majdzadeh R, Heidarzadeh A. Rationale, methods and first results of the Iranian national programme for prevention of chronic diseases from childhood: CASPIAN study. East Mediterr Health J 2009;15:302-14.

20. Kelishadi R, Heshmat R, Motlagh ME, Majdzadeh R, Keramatian K, Qorbani M, et al. Methodology and early findings of the third survey of CASPIAN study: a national school-based surveillance of students' high risk behaviors. Int J Prev Med 2012;3:394-401.

21. Motlagh ME, Ziaodini H, Qorbani M, Taheri M, Aminaei T, Goodarzi A, et al. Methodology and early findings of the fifth survey of childhood and adolescence surveillance and prevention of adult noncommunicable disease: the CASPIAN-V study. Int J Prev Med 2017;8:4.

22. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1995;854:1-452.

23. WHO Multicentre Growth Reference Study Group. Who child growth standards based on length/height, weight and age. Acta Paediatr Suppl 2006;450:76-85.

24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.

25. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821-7.

26. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140:e20171904.

27. Mazaheri-Tehrani S, Yazdi M, Heidari-Beni M, Yazdani Z, Kelishadi R. The association between vitamin C dietary intake and its serum levels with anthropometric indices: a systematic review and meta-analysis. Complement Ther Clin Pract 2023;51:101733.

28. Mazaheri-Tehrani S, Kelishadi R. COVID-19 and the prevalence of physical inactivity. In: Selk-Ghaffari M, Memari A, Mahdaviani B, Kordi R, editors. Physical activity and pandemics: lessons learned from COVID-19. Singapore: Springer Nature; 2023:1-8.

29. Alizadeh A, Negarandeh R, Bagheri Amiri F, Yazdani Z. The study of Iranian children and adolescents' physical activity: a systematic review and meta-analysis. Int J Adolesc Med Health 2021;33:65-74.

30. Baradaran Mahdavi S, Mazaheri-Tehrani S, Riahi R, Vahdatpour B, Kelishadi R. Sedentary behavior and neck pain in children and adolescents; a systematic review and metaanalysis. Health Promot Perspect 2022;12:240-8.

31. Ooi DS, Ong SG, Lee OM, Chan YH, Lim YY, Ho CW, et al. Prevalence and predictors of metabolically healthy obesity in severely obese Asian children. Pediatr Res 2022;92:1374-80.

32. Videira-Silva A, Freira S, Fonseca H. Metabolically healthy overweight adolescents: definition and components. Ann Pediatr Endocrinol Metab 2020;25:256-64.

33. Gao M, Lv J, Yu C, Guo Y, Bian Z, Yang R, et al. Metabolically healthy obesity, transition to unhealthy metabolic status, and vascular disease in Chinese adults: a cohort study. PLoS Med 2020;17:e1003351.

34. Abiri B, Koohi F, Ebadinejad A, Valizadeh M, Hosseinpanah F. Transition from metabolically healthy to unhealthy overweight/obesity and risk of cardiovascular disease incidence: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 2022;32:2041-51.

35. Sénéchal M, Wicklow B, Wittmeier K, Hay J, MacIntosh AC, Eskicioglu P, et al. Cardiorespiratory fitness and adiposity in metabolically healthy overweight and obese youth. Pediatrics 2013;132:e85-92.

36. Arefian M, Mazaheri-Tehrani S, Yazdi M, Kelishadi R. Caveolin gene, a possible risk factor for metabolic syndrome in humans: a systematic review and meta-analysis. Int J Prev Med 2025;16:7.

37. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981;34:1617-21.

38. Karandish M, Hosseinpour M, Rashidi H, Latifi SM, Moravej Aleali A. Comparison of components of metabolic syndrome among metabolically obese normal weight, metabolically benign normal weight, and metabolically abnormal obese Iranian children and adolescents in Ahvaz. J Nutr Secur 2016;1:9-15.